interleukin-4


Also found in: Dictionary, Thesaurus, Medical.

interleukin-4

[‚in·tər′lük·ən ′fȯr]
(immunology)
A cytokine that is capable of a variety of activities, such as induction of proliferation by T cells, mast cells, megakarocytes, and erythroid precursors; induction of antibody secretion by B cells; and potentiation of the proliferation of mast cells. Abbreviated IL-4.
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
Gustchina, "Crystal structure of human recombinant interleukin-4 at 2.25 A resolution," FEBS Letters, vol.
Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists," Respiratory Research, vol.
Interleukin-4 Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy.
KEY WORDS: Blood shell, Scapharca broughtonii, Interleukin-4, EL4 T cell, NF-AT
Some research has suggested that interleukin-4 regulates cells' capacity to display receptors for morphine, codeine, or other opioids.
A nebulized protein to soak up interleukin-4 also was promising initially, and had the advantage of only having to be administered every few weeks.
Further, the data show induction of MCP-1 and mRNA by OSM in both cell types tested and significant attenuation by KPL-716 of the cellular MCP-1 response to OSM and the synergistic response to OSM and interleukin-4, or IL-4.
It is a targeted biologic therapy that inhibits signalling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two key proteins that are likely to play a central role in type two inflammation that underlies atopic dermatitis and several other allergic diseases.
The well-tolerated protein, called interleukin-4, works as well as a powerful standard therapy known to cause severe side effects.
SAN DIEGO -- An inhaled recombinant interleukin-4 receptor antagonist was well tolerated and caused no serious adverse events in adult patients with moderate asthma, Dr.
The '487 patent relates to compositions and methods for treating certain conditions induced by interleukin-4 by administering an IL-4 antagonist to a patient with such a condition.
The product is a human monoclonal antibody specifically designed to inhibit signalling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two important signalling proteins (cytokines) that contribute to Type 2 inflammation in moderate-to-severe asthma.